Your donation will make a difference:
Cystic Fibrosis Trust
Forum

Trials Tracker

Welcome to the Trials Tracker, bringing together all the cystic fibrosis (CF) trials currently recruiting in the UK so that you can find clinical trials you can take part in both in your region and further afield. The Trials Tracker is a new resource that we’ll be developing over time based on your feedback. If you’ve used the Trials Tracker and want to share your opinion, please complete our online poll or get in touch at clinicaltrials@cysticfibrosis.org.uk.

Please Log in

Log in

Not a registered user? Register with us

This trial has been added to your watchlist.

Do you want to receive email notifications when the trial status changes?

No Yes

Unfollowing a trial will remove it from the watchlist and stop status change email notifications

Are you sure you want to unfollow this trial?

Yes, remove from watchlist

Clinical trials

36-40 of 52 results for all trials

Sort by:

Filter by

Trial status

Inclusion age

FEV1

Trial type

Location

Mutation

Therapeutic category

Flamingo

Cystic fibrosis is caused by changes in the genes of your DNA (Deoxyribonucleic Acid) encoding for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein. These changes cause the CFTR to stop working as it should. CFTR is a protein present in some specific cells of the body and its correct functioning is important for those cells. GLPG2222 is being studied for treatment of cystic fibrosis. The study drug is designed to improve the amount and function of CFTR, which may improve some of the symptoms of cystic fibrosis. The purpose of this study is to find out whether GLPG2222, taken by mouth as tablet once a day, is safe, well-tolerated and effective in improving your signs and symptoms of cystic fibrosis. The study will also evaluate how the body takes in and breaks down the study drug (GLPG2222). The amount of drug in your blood will be measured at specific study visits after you start taking the drug. These measurements will show how quickly the drug is taken up by the body, how quickly it is broken down, when it reaches a steady level in the blood, and how long it stays in the body.

Read more
  • Trial Reference Number

    94989

  • Mutation

    Two copies of F508del (delta F508)

  • Age

    18+

  • Length of participation

    6 - 10 weeks

  • Trial status

    Closed to recruitment - in follow up

  • Therapeutic category

    Restore CFTR Function

A study of FDL169 in subjects with Cystic Fibrosis

This is a randomized, placebo controlled, double-blinded study. 24 CF subjects will be assigned randomly to two groups, active drug or placebo. Three doses of FDL169 or placebo will be given 3 times a day for 28 days. The aim of this clinical study is to test how well CF subjects tolerate FDL169. In addition, the study will also test how subjects’ bodies absorb and digest FDL169 by measuring study subjects’ blood at specific intervals after taking the tablet orally.

Read more Phase I
  • Trial Reference Number

    90508

  • Mutation

    Two copies of F508del (delta F508)

  • Age

    18+

  • Length of participation

    28 days

  • Trial status

    Completed

  • Therapeutic category

    Restore CFTR Function

Experiences of Living with Cystic Fibrosis; The impact on children, young people, adults and their families

Through interviewing both the patient with CF and their families, this study hopes to establish a clearer picture of the effect the condition can have on the individual themselves and on their immediate family, in various aspects of their lives. From this, we hope to understand the key challenges facing these populations to help tailor the development of services.

Read more
  • Trial Reference Number

    95222

  • Length of participation

    1 day

  • Trial status

    Open

  • Therapeutic category

    Behavioral

How PWCF interpret and respond to the PAM-13

Cystic Fibrosis affects 10,000 people in the United Kingdom (UK). People with Cystic Fibrosis (PWCF) typically die from lung damage at a median age of 28 years. Randomised controlled trials show that preventative medications reduce exacerbations and/or preserve lung function. However adherence is poor. We have been funded to undertake a five year programme to develop and evaluate a new approach to helping PWCF adhere to their nebulisers. We have undertaken a number of studies as part of this full programme and all have received a favourable opinion from an NHS REC. This study focuses on the usage of the PAM-13 which is being used as one of the secondary outcome measures to evaluate the intervention we developed. While we would expect that people with higher patient activation scores or levels would have higher levels of adherence no such pattern could be discerned from an initial analysis of the pilot trial baseline data (WP 3.1, Arden et al., unpublished). This has led to the question of how patients with Cystic Fibrosis in the UK interpret and respond to the PAM-13. Given the limited existing evidence of the effectiveness of the PAM-13 in UK patients, especially those with multiple co-morbidities, it is for the ACtiF programme, as well as the usage of the PAM-13 across the UK in a range of contexts that we understand how people are interpreting and responding to the items of the PAM-13. This study therefore aims to use a 'think-aloud' methodology to investigate how people with CF, and with other co-morbidities, understand and answer the PAM-13.

Read more Not Applicable
  • Trial Reference Number

    94612

  • Age

    18+

  • Length of participation

    1 day

  • Trial status

    Completed

  • Therapeutic category

    Behavioral

CFHealthHub Data Observatory

Cystic Fibrosis (CF) affects 10000 people in the UK. The lungs of people with CF (PWCF) are prone to infections and require daily medication to stay healthy. Average adherence to medication has shown to be only 36%. Poor adherence is associated with poor clinical outcomes including distressing unscheduled hospitalisations. Previous research has been undertaken to design a website (CFHealthhub) which records personal adherence data using chipped nebulisers and understand whether this can build successful treatment habits. In the current project we will develop CFHealthHub as a data observatory which will record adherence data and other indicators of health and patient care held in patient notes. The purpose of this is two- fold; to support local and national Quality Improvement (QI) projects aiming to improve an individual’s adherence to treatment and the quality of care delivered by the CF centre. Secondly, collecting adherence data from a large number of PWCF may support future research studies whereby CFHealthHub is used as a source of participants and data. We aim to recruit PWCF who use chipped nebulisers from 4 CF centres across in England. PWCF will be consented to 1) share their identifiable data with their local CF team 2) share data, from which they cannot be identified, with all CF centres in the study 3) share data, from which they cannot be identified, in future research studies which result in no changes to their care and 4) share data to be included for selection to future studies which may result in changes to care, such as testing new treatments. Consent in any combination can be provided and withdrawn at any time. Participants who consent to 'selection' for future studies will also be provided with information specific to the new study and the opportunity to decline participation, if selected from the data observatory.

Read more Not Applicable
  • Trial Reference Number

    95070

  • Length of participation

    Up to 6 years

  • Trial status

    Open to recruitment

  • Therapeutic category

    Behavioral

36-40 of 52 results for all trials